Thermo Fisher Scientific (NYSE:TMO) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $10.80-10.96 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.84. The company issued revenue guidance of $23.62-23.86, compared to the consensus revenue estimate of $23.62 billion.
A number of research firms have commented on TMO. Morgan Stanley reduced their price objective on Thermo Fisher Scientific from $228.00 to $216.00 and set an overweight rating on the stock in a research note on Wednesday, April 11th. Zacks Investment Research lowered Thermo Fisher Scientific from a buy rating to a hold rating in a research note on Thursday, April 5th. ValuEngine upgraded Thermo Fisher Scientific from a hold rating to a buy rating in a research note on Friday, February 2nd. Bank of America raised their price objective on Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a buy rating in a report on Thursday, February 1st. Finally, Barclays raised their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an overweight rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific currently has an average rating of Buy and an average target price of $220.64.
Thermo Fisher Scientific stock opened at $215.50 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a 1-year low of $160.99 and a 1-year high of $226.44. The stock has a market cap of $86,925.99, a PE ratio of 22.46, a PEG ratio of 1.60 and a beta of 1.15.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm had revenue of $5.85 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period last year, the business earned $2.08 earnings per share. The business’s revenue was up 22.8% on a year-over-year basis. sell-side analysts predict that Thermo Fisher Scientific will post 10.84 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, April 16th. Investors of record on Thursday, March 15th were given a dividend of $0.17 per share. The ex-dividend date was Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.17%.
In other Thermo Fisher Scientific news, Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $209.80, for a total value of $209,800.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Gregory J. Herrema sold 33,327 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the sale, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The disclosure for this sale can be found here. Insiders have sold 88,827 shares of company stock valued at $19,012,672 in the last three months. 0.49% of the stock is owned by insiders.
An institutional investor recently raised its position in Thermo Fisher Scientific stock. Ark Investment Management LLC lifted its holdings in Thermo Fisher Scientific (NYSE:TMO) by 2.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,005 shares of the medical research company’s stock after buying an additional 488 shares during the period. Ark Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $3,141,000 at the end of the most recent reporting period. Institutional investors own 87.19% of the company’s stock.
WARNING: “Thermo Fisher Scientific (TMO) Issues FY18 Earnings Guidance” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/25/thermo-fisher-scientific-tmo-issues-fy18-earnings-guidance.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.